Announcements Trials
Browse Landscape

Phase

Phase 1 233Phase 1/2 69Phase 2 49Phase NA 15Phase EARLY_PHASE1 8Phase 3 3Phase 4 1Phase 2/3 1

Status

Completed 6Recruiting 3Unknown 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 29Thoracic 21Breast 14Other hematologic neoplasm 13Genitourinary 11Lymphoid 10Gynecologic 9Head & Neck 8Dermatologic 6CNS 6Sarcoma 5Myeloid 5Plasma cell 4Tumor-Agnostic 3Other 2Endocrine 2Other solid neoplasm 1NET 1Classical hematology 1

Conditions

Mesothelioma 1

Interventions

nintedanib 1Pemetrexed 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Other solid neoplasm × Clear all
NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Boehringer Ingelheim

Phase 2/3 Terminated
545 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡